{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:21:34Z","timestamp":1760984494699},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T00:00:00Z","timestamp":1347235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives\/Hypothesis:<\/jats:title><jats:p>Although contraindicated, neomycin otic preparations may be administered to children with nonintact tympanic membranes (TMs), such as tympanostomy tubes or TM perforations. The goal of this study was to assess the magnitude of neomycin exposure in children with nonintact TMs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design:<\/jats:title><jats:p>Retrospective drug utilization study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Medicaid claims data (years 1999\u20132006) from 28 states for children aged 0 to 18 years were analyzed to identify new cases of tube placement or TM perforation. Cases were followed for 12 months to determine neomycin otic utilization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Of the 300,470 children with nonintact TMs, neomycin otic preparations were prescribed in 43,815 (15%). Nontoxic agents (ofloxacin or ciprofloxacin) were used in 48%. In 19%, neomycin preparations were prescribed at the day of initial nonintact TM diagnosis, 52% and 71% within the first 3 or 6 months, respectively. Neomycin otic utilization decreased from 27% in cases diagnosed in 1999 to 7% in 2005 (<jats:italic>P<\/jats:italic> &lt; .0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Many children with nonintact TMs receive exposure to agents with potential ototoxicity, despite the availability of safer alternatives. Further study is necessary to determine why neomycin otic preparations continue to be prescribed in the presence of nonintact TMs and if such exposure is associated with ototoxicity. Laryngoscope, 2012<\/jats:p><\/jats:sec>","DOI":"10.1002\/lary.23554","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T18:58:24Z","timestamp":1347303504000},"page":"2529-2532","source":"Crossref","is-referenced-by-count":12,"title":["Ototopical neomycin exposure in children with nonintact tympanic membranes"],"prefix":"10.1002","volume":"122","author":[{"given":"Almut G.","family":"Winterstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M. Hincapie","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1947.02880020013004"},{"key":"e_1_2_7_3_2","first-page":"141","article-title":"Ototoxicity and ototopical medications: a survey of otolaryngologists","volume":"14","author":"Lundy LB","year":"1993","journal-title":"Am J Otol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.03.009"},{"key":"e_1_2_7_5_2","unstructured":"StreeterMA HeaberlinBK GalTJ JonesRO.Prospective randomized study of the effect of topical antimicrobial therapy on post\u2010tympanostomy tube otorrhea and tube occlusion. Paper presented at: Triological Society Combined Sections Meeting; February2010; Orlando FL."},{"key":"e_1_2_7_6_2","first-page":"27","article-title":"The effectiveness of topical treatment in discharging ears with in\u2010dwelling ventilation tubes","volume":"121","author":"Strachan D","year":"2000","journal-title":"Rev Laryngol Otol Rhinol (Bord)"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.12.1294"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2003.12.007"},{"key":"e_1_2_7_9_2","first-page":"194","article-title":"Safety of topical ear drops containing ototoxic antibiotics","volume":"26","author":"Rakover Y","year":"1997","journal-title":"J Otolaryngol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199505000-00003"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2000.107888"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-197608000-00009"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2273.1994.tb01198.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/00034894900990S613","article-title":"Round window membrane permeability during experimental purulent otitis media: altered Cortisporin ototoxicity","volume":"148","author":"Ikeda K","year":"1990","journal-title":"Ann Otol Rhinol Laryngol Suppl"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.31"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7471.867"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/01050398609045956"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115198"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.126.12.1440"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.131.9.782"},{"key":"e_1_2_7_21_2","unstructured":"Monarch PharmaceuticalsI. Cortisporin\u2014neomycin sulfate polymyxin b sulfate and hydrocortisone solution [package insert]. Available at:http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=483d9903\u20105b09\u2010450f\u20102b86\u20106625345068eb. Accessed January 8 2012."},{"key":"e_1_2_7_22_2","first-page":"495","article-title":"Ototoxicity of neomycin and polymyxin B following middle ear application in the chinchilla and baboon","volume":"8","author":"Wright CG","year":"1987","journal-title":"Am J Otol"},{"key":"e_1_2_7_23_2","first-page":"207","article-title":"In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics","volume":"17","author":"Dohar JE","year":"1996","journal-title":"Am J Otol"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flary.23554","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.23554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:57:54Z","timestamp":1697482674000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.23554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,10]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/lary.23554"],"URL":"https:\/\/doi.org\/10.1002\/lary.23554","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,10]]}}}